Ginkgo Bioworks Holdings, Inc.

NYSE:DNA Stock Report

Market Cap: US$401.2m

Ginkgo Bioworks Holdings Past Earnings Performance

Past criteria checks 0/6

Ginkgo Bioworks Holdings's earnings have been declining at an average annual rate of -8.1%, while the Chemicals industry saw earnings growing at 10.2% annually. Revenues have been growing at an average rate of 10.3% per year.

Key information

-8.1%

Earnings growth rate

-2.5%

EPS growth rate

Chemicals Industry Growth12.9%
Revenue growth rate10.3%
Return on equity-76.4%
Net Margin-240.9%
Next Earnings Update06 May 2025

Recent past performance updates

Recent updates

Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 28% But Its Business Is Yet to Catch Up

Apr 27
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 28% But Its Business Is Yet to Catch Up
author-image

Biopharma Demand Will Boost Automation And Data Services

Mar 27 Shifting towards tools like Ginkgo Automation platform addresses biopharma AI data demand, enhancing revenue through diversification.

These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat

Mar 01
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat

2025 Is Make Or Break For Ginkgo Bioworks

Feb 27

Revenues Not Telling The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) After Shares Rise 39%

Feb 13
Revenues Not Telling The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) After Shares Rise 39%

Ginkgo Bioworks: Declining Core Revenue And High Cash Burn Echo Amyris' Path

Jan 30

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 15
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Ginkgo Bioworks: Not Enough Progress

Nov 13

Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%

Oct 04
Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%

Ginkgo Bioworks: Here Comes The Test

Aug 22

The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%

Aug 16
The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%

Ginkgo Bioworks: Losing A Major Supporter

Jun 25

Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump

Jun 18
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

May 11
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Ginkgo Bioworks: Broken Narrative

May 10

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Apr 26
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts

Mar 06
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts

With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For

Mar 01
With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For

Ginkgo Bioworks: More Awful Revenue Guidance

Mar 01

Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment

Jan 26

Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty

Dec 20

Ginkgo Bioworks: A Long Way To Go

Nov 21

News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat

Nov 13
News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat

Ginkgo Bioworks: More Revenue Issues

Nov 13

Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Nov 10
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Porter's 5 Forces Suggest That Ginkgo Is A Buy

Oct 25

Ginkgo Bioworks: Products Progressing Towards Market

Oct 10

Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)

Aug 30

Ginkgo Bioworks: Lack Of Progress Is A Concern

Aug 18

Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)

Aug 10

Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds

Jun 23

Revenue & Expenses Breakdown

How Ginkgo Bioworks Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:DNA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 24227-547237424
30 Sep 24218-651250465
30 Jun 24184-898297544
31 Mar 24209-854310554
31 Dec 23251-893351581
30 Sep 23315-857382641
30 Jun 23326-1,224713746
31 Mar 23390-1,7191,080892
31 Dec 22478-2,1051,4031,053
30 Sep 22528-3,5302,0881,860
30 Jun 22539-2,9621,6831,652
31 Mar 22438-2,3471,2791,414
31 Dec 21314-1,8308631,150
30 Sep 21197-27694226
30 Jun 21133-20075209
31 Mar 21100-17550189
31 Dec 2077-12738160
31 Dec 1954-1192996

Quality Earnings: DNA is currently unprofitable.

Growing Profit Margin: DNA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DNA is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.

Accelerating Growth: Unable to compare DNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DNA is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-3.7%).

Return on Equity

High ROE: DNA has a negative Return on Equity (-76.39%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/30 22:46
End of Day Share Price 2025/04/30 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ginkgo Bioworks Holdings, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael RyskinBofA Global Research
Mark MassaroBTIG
Matthew SykesGoldman Sachs